ESR1 and cancer: Our approach confirmed the role of previously described cancer-type-specific driver-induced SV phenotypes, including homologous recombination deficiency33 in metastatic breast carcinoma tumours, CDK12 (ref. 34) alterations in prostate carcinoma and MDM2 (ref. 35) amplifications in breast ER+/HER2− carcinomas, among others.